Shares rallied 4.7% in premarket trading.Orphazyme (ORPH)– Orphazyme plunged 52.6% in the premarket after the Food and Drug Administration rejected its speculative treatment for a hereditary disorder known as Niemann-Pick disease type C. Arcelor-Mittal rose 1% in premarket action, while Cleveland-Cliffs added 0.3%. Biogen shares rose 1.7% in the premarket.Citigroup (C)– The banks stock remains on watch after declining for the past 11 successive trading days, losing 14% over that time.
